跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

B7148

Sigma-Aldrich

丁螺环酮盐酸盐 盐酸盐

≥99% (TLC), powder, 5-HT1A serotonin receptor agonist

别名:

N-[4-[4-(2-嘧啶基)-1-哌嗪基] 丁基]-8-氮杂螺[4.5]癸烷-7,9-二酮 盐酸盐

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C21H31N5O2 · HCl
CAS号:
33386-08-2
分子量:
421.96
EC號碼:
251-489-4
MDL號碼:
MFCD00078569
分類程式碼代碼:
12352200
PubChem物質ID:
24278079
NACRES:
NA.77

product name

丁螺环酮盐酸盐 盐酸盐,

形狀

powder

品質等級

100

起源

Bristol-Myers Squibb

儲存溫度

2-8°C

SMILES 字串

Cl[H].O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4

InChI

1S/C21H31N5O2.ClH/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20;/h5,8-9H,1-4,6-7,10-17H2;1H

InChI 密鑰

RICLFGYGYQXUFH-UHFFFAOYSA-N

基因資訊

human ... HTR1A(3350)

正在寻找类似产品? 访问 产品对比指南

生化／生理作用

5-HT 1A 血清素受体激动剂；抗焦虑药。

特點和優勢

该化合物由Bristol-Myers Squibb开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
这种化合物是神经科学研究的特色产品。 点击此处 ，发现更多特色神经科学产品。访问sigma.com/discover-bsm了解更多关于其他研究领域的生物活性小分子的信息。

象形圖

Skull and crossbones
GHS06

訊號詞

Danger

危險聲明

H301

危險分類

Acute Tox. 3 Oral

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

E Meller et al.
Molecular pharmacology, 37(2), 231-237 (1990-02-01)
The irreversible receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was used to determine the relationship between receptor occupancy and response at central 5-hydroxytryptamine1A (5-HT1A) serotonin receptors mediating the inhibition of serotonin synthesis in rat cortex and hippocampus. Rats were treated with vehicle or
G Tunnicliff
Pharmacology & toxicology, 69(3), 149-156 (1991-09-01)
Buspirone has been available in the United States for over four years for the treatment of anxiety. It was anticipated this drug would offer certain advantages over the established benzodiazepines. In contrast to diazepam, early studies found no evidence for
Roy H Perlis et al.
The Journal of clinical psychiatry, 73(11), 1439-1442 (2012-10-13)
A subset of patients undergoing initial antidepressant treatment experience worsening of symptoms, including thoughts of suicide or suicidal behavior. The present study explores whether this subset of patients is also more likely to experience recurrence or worsening of these symptoms
Repurposing buspirone for drug addiction treatment.
Bernard Le Foll et al.
The international journal of neuropsychopharmacology, 16(2), 251-253 (2012-11-24)
Mohammad-Reza Mohammadi et al.
Acta medica Iranica, 50(11), 723-728 (2013-01-08)
A recent randomized clinical trial showed buspirone efficacy in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children. However, results from a recent multi-site controlled clinical trial of transdermal buspirone failed to separate it from placebo in a large sample of
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门